Elevated circulating interleukin 33 levels in stable renal transplant recipients at high risk for cardiovascular events

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Mansell, Holly ^a   Soliman, Mahmoud ^b   Elmoselhi, Hamdi ^b   Shoker, Ahmed ^b,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Health Region St Pauls Hospital   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; PHOSPHATE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; KIDNEY GRAFT; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PHOSPHATE BLOOD LEVEL; POPULATION RISK; RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; KIDNEY TRANSPLANTATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTERLEUKIN-33; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84952651196     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142141     Document Type: Article

References (65)

1. Lloyd-Jones D. M. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010 121, 1768-1777. doi:10.1161/CIRCULATIONAHA.109.849166 PMID: 20404268
2. Mansell H., Stewart S., Shoker A. Validity of cardiovascular risk prediction models in kidney transplant recipients: a systematic review. The Scientific World Journal vol. 2014, Article ID 750579. doi:10.1155/2014/750579 PMID: 24977223
3. Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellstrom B. A cardiovascular risk calculator for renal transplant recipients. Transplantation 2012;94:57-62. doi:10.1097/TP.0b013e3182516cdc PMID: 22683851
4. Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec. 19-26;420(6917):868-74 PMID: 12490960
5. Packard RR1, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008 Jan; 54(1):24-38. PMID: 18160725
6. Hansson GK1, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011 Mar; 12(3):204-12. doi:10.1038/ni.2001 PMID: 21321594
7. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010 Feb; 74(2):213-20. Epub 2010 Jan 9. PMID: 20065609
8. Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005 May 1;66(2):265-75. Epub 2005 Jan 28. PMID: 15820195
9. Cortez-Cooper M1, Meaders E, Stallings J, Haddow S, Kraj B, Sloan G, et al. Soluble TNF and IL-6 receptors: indicators of vascular health in women without cardiovascular disease. Vasc Med. 2013 Oct; 18(5):282-9. doi:10.1177/1358863X13508336 PMID: 24165468
10. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005 Apr; 67(4):1216-33. PMID: 15780075
11. Abedini Sadollah, Holme Ingar, Winfried März, Gisela Weihrauch, Bengt Fellström, Alan Jardine, et al, and on behalf of the ALERT study group. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009:4:1246.
12. Mansell H, Elmoselhi H, Shoker A. Association between Circulating Thrombopoietin Levels and Cardiovascular Risk Prediction Scores in Renal Transplant Recipients. Am J Nephrol. 2015;41(2):147-55. doi:10.1159/000377641 Epub 2015 Mar. 19. PMID: 25824430
13. Mansell H, Rosaasen N, Dean J, Shoker A. Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores. Clin Transplant. 2013 Jul-Aug; 27(4):E391-9. doi:10.1111/ctr.12159 Epub 2013 Jun. 19. PMID: 23782452
14. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011 Aug. 26;8(1):22. doi:10. 1186/1476-9255-8-22
15. Liu Q, Turnquist HR. Implications for Interleukin-33 in solid organ transplantation. Cytokine. 2013 May; 62(2):183-94. doi:10.1016/j.cyto.2013.02.026 Epub 2013 Mar. 27. PMID: 23541899
16. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014 Dec; 31:31-7. doi:10.1016/j.coi.2014.09.004 Epub 2014 Sep. 29. PMID: 25278425
17. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012 Apr; 52(1-2):89-99. doi:10.1007/s12026-012-8283-9 PMID: 22392053
18. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007 Jun; 117(6):1538-49. Epub 2007 May 10. PMID: 17492053
19. Barbour M, Allan D, Xu H, Pei C, Chen M, Niedbala W, et al. IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol. 2014 Nov; 44(11):3320-9. doi:10.1002/eji.201444671 Epub 2014 Oct. 18. PMID: 25116404
20. Jiang HR, Milovanović M, Allan D, Niedbala W, Besnard AG, Fukada SY et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur J Immunol. 2012 Jul; 42(7):1804-14. doi:10.1002/eji.201141947 Epub 2012 Jun. 12. PMID: 22585447
21. Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol. 2014 Oct. 15;193(8):4010-20. doi:10.4049/jimmunol. 1400481 Epub 2014 Sep. 12. PMID: 25217167
22. Pomeshchik Y, Kidin I, Korhonen P, Savchenko E, Jaronen M, Lehtonen S, et al. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav Immun. 2015 Feb; 44:68-81. doi:10.1016/j.bbi.2014.08.002 Epub 2014 Aug. 18. PMID: 25153903
23. Zhao Q, Chen G. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int. 2014;2014:587376. doi:10.1155/2014/587376 Epub 2014 Jun. 16. PMID: 25032216
24. Thierry A, Giraud S, Robin A, Barra A, Bridoux F, Ameteau V, et al. The alarmin concept applied to human renal transplantation: evidence for a differential implication of HMGB1 and IL-33. PLoS One. 2014 Feb. 20;9(2):e88742. doi:10.1371/journal.pone.0088742. eCollection 2014 PMID: 24586382
25. Murphy GE, Xu D, Liew FY, McInnes IB. Role of interleukin 33 in human immunopathology. Ann Rheum Dis. 2010 Jan; 69 Suppl 1:i43-47. doi:10.1136/ard.2009.120113 PMID: 19995743
26. Salas A. The IL-33/ST2 axis: yet another therapeutic target in inflammatory bowel disease? Gut. 2013 Oct; 62(10):1392-3. doi:10.1136/gutjnl-2012-303920 Epub 2013 Jan 11. PMID: 23315502
27. Yin H, Li XY, Jin XB, Zhang BB, Gong Q, Yang H, et al. IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation. 2010 May 27;89(10):1189-97. doi: 10.1097/TP.0b013e3181d720af PMID: 20220570
28. Brunner SM, Schiechl G, Falk W, Schlitt HJ, Geissler EK, Fichtner-Feigl S. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int. 2011 Oct; 24(10):1027-39. doi:10.1111/j. 1432-2277.2011.01306.x Epub 2011 Jul. 28. PMID: 21797940
29. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008 Feb. 18;205(2):339-46. doi:10.1084/jem.20071868 Epub 2008 Feb. 11. PMID: 18268038
30. McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, et al. IL-33 reduces macrophage foam cell formation J Immunol, 2010 185(2), pp. 1222-1229 doi:10.4049/jimmunol. 1000520 PMID: 20543107
31. Hasan A, Al-Ghimlas F, Warsame S, Al-Hubail A, Ahmad R, Bennakhi A, et al. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol. 2014 May 10;15:19. doi:10.1186/1471-2172-15-19 PMID: 24886535
32. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood. 2009 Oct. 1;114(14):3117-26. doi:10.1182/blood-2009-02-203372 Epub 2009 Aug. 6. PMID: 19661270
33. Liu J, Xing Y, Gao Y, Zhou C. Changes in serum interleukin-33 levels in patients with acute cerebral infarction. J Clin Neurosci. 2014 Feb; 21(2):298-300. doi:10.1016/j.jocn. 2013.04.036 Epub 2013 Nov. 5. PMID:24210798
34. Akcay A, Nguyen Q, He Z, Turkmen K, Won Lee D, Hernando AA, et al. IL-33 Exacerbates Acute Kidney Injury. J Am Soc Nephrol. 2011 Nov; 22(11):2057-67. doi:10.1681/ASN.2010091011 Epub 2011 Sep. 23. PMID: 21949094
35. Bao YS, Na SP, Zhang P, Jia XB, Liu RC, Yu CY, et al. Characterization of Interleukin-33 and Soluble ST2 in Serum and Their Association with Disease Severity in Patients with Chronic Kidney Disease. J Clin Immunol. 2012 Jun; 32(3):587-94. doi:10.1007/s10875-011-9622-7 Epub 2011 Dec. 28. PMID: 22203232
36. Arnlöv J., Evans J. C., Meigs J. B., Wang T. J., Fox C. S., Levy D., et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005 Aug. 16;112(7):969-75. Epub 2005 Aug. 8. PMID: 16087792
37. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A.. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989 Apr; 32(4):219-26. PMID: 2668076
38. Calvo MS, Uribarri J. Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population. Am J Clin Nutr. 2013 Jul; 98(1):6-15. doi:10.3945/ajcn. 112.053934 Epub 2013 May 29. PMID: 23719553
39. Menon MC, Ix JH. Dietary phosphorus, serum phosphorus, and cardiovascular disease. Ann N Y Acad Sci. 2013 Oct; 1301:21-6. doi:10.1111/nyas.12283 Epub 2013 Sep. 30. PMID: 24117725
40. Foley RN1, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009 Feb; 20(2):397-404. doi:10.1681/ASN. 2008020141 Epub 2008 Nov. 5. PMID: 18987306
41. Kuroo M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997 Nov. 6;390(6655):45-51 PMID: 9363890
42. Tonelli M1, Sacks F, Pfeffer M, Gao Z, Curhan G. Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33. PMID: 16246962
43. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int. 2002 Apr; 61(4):1486-94. PMID: 11918756
44. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007 Jul. 3;116(1):85-97. PMID: 17606856
45. Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014 Apr. 21;9(4):e95055. doi:10.1371/journal.pone.0095055.eCollection2014 PMID: 24751794
46. Miller AM Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011 Aug. 26;8(1):22. doi:10. 1186/1476-9255-8-22
47. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004 May 11;109(18):2186-90. Epub 2004 Apr. 26. PMID: 15117853
48. Zhang K1, Zhang XC, Mi YH, Liu J. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J (Engl). 2013;126(19):3628-31.
49. Liu CL, Shen DL, Zhu K, Tang JN, Wang XF, Zhang L, et al. Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease. Coron Artery Dis. 2014 Sep; 25(6):498-504. doi:10.1097/MCA. 0000000000000117 PMID: 24710352
50. Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol. 2013 Sep. 1;167(5):2182-8. doi:10.1016/j.ijcard.2012.05.073 Epub 2012 Jul. 24. PMID:22835988
51. Schuett H1, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009 Aug; 102(2):215-22. doi:10.1160/TH09-05-0297 PMID: 19652871
52. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001;286:2107-2113.
53. Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, et al, and TIMI Study Group. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006;97:1473-1477. PMID: 16679086
54. Fontes JA, Rose NR, Čiháková D. The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine. 2015 Jul; 74(1):62-68. doi:10.1016/j.cyto.2014.12.024 Epub 2015 Jan 31. PMID: 25649043
55. De Serres SA, Mfarrej BG, Grafals M, Riella LV, Magee CN, Yeung MY, et al. Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin J Am Soc Nephrol. 2012 Jun; 7(6):1018-25. doi:10.2215/CJN.11051011 Epub 2012 Apr. 12. PMID: 22498498
56. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis. 2002 Jan; 160(1):91-102 PMID: 11755926
57. Sánchez-Escuredo A1, Pastor MC, Bayés B, Morales-Indiano C, Troya M, Dolade M, et al. Inflammation, metalloproteinases, and growth factors in the development of carotid atherosclerosis in renal transplant patients. Transplant Proc. 2010 Oct; 42(8):2905-7. doi:10.1016/j.transproceed.2010.07. 076 PMID: 20970566
58. Gregersen I, Skjelland M, Holm S, Holven KB, Krogh-Sørensen K, Russell D, et al. Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis. PLoS One. 2013 Aug. 30;8(8):e72769. doi:10.1371/journal.pone.0072769 eCollection 2013. PMID: 24023645
59. Shabgah AG, Fattahi E, Shahneh FZ. Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol. 2014 Aug; 31(4):256-61. doi:10.5114/pdia.2014.40954 Epub 2014 Sep. 8. Review. PMID: 25254011
60. Millán O, Rafael-Valdivia L, San Segundo D, Boix F, Castro-Panete MJ, López-Hoyos M, et al. Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. Clin Immunol. 2014 Oct; 154(2):141-54. doi:10.1016/j.clim. 2014.07.007 Epub 2014 Aug. 1. PMID: 25088788
61. Saini D, Weber J, Ramachandran S, Phelan D, Tiriveedhi V, Liu M, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant. 2011 Jun; 30(6):624-31. doi:10.1016/j.healun. 2011.01.708 Epub 2011 Mar. 16 PMID: 21414808
62. Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein (a). J Am Coll Cardiol. 2014 May 6;63(17):1724-34. doi:10.1016/j. jacc.2013.12.030 Epub 2014 Feb. 12. PMID: 24530664
63. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophagestimulating cytokines. Atherosclerosis 1999;145:33-43. PMID: 10428293
64. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003 Aug; 8(3):223-46. PMID: 12946237
65. Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED, et al. and PORT Investigators. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010;10:338-5 doi:10.1111/j.1600-6143.2009.02949.x PMID: 20415903